Compare TGL & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGL | XBIO |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 7.5M |
| IPO Year | 2022 | N/A |
| Metric | TGL | XBIO |
|---|---|---|
| Price | $3.65 | $3.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 38.5K | 22.4K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,330,557.00 | N/A |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $1.90 |
| 52 Week High | $58.00 | $13.93 |
| Indicator | TGL | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 58.50 |
| Support Level | $3.40 | $2.59 |
| Resistance Level | $9.45 | $3.12 |
| Average True Range (ATR) | 0.35 | 0.19 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 29.99 | 69.23 |
Treasure Global Inc has created an online-to-offline e-commerce platform business model that offers consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retail or merchant settings. Its product is an internet application branded as the ZCITY app, which targets consumers by providing personalized deals based on their purchase history, location, and preferences. The Company has two reportable segments: payment processing and e-commerce operation in its ZCITY platform, and customized software development service, and the majority of revenue comes from payment processing and e-commerce operation in its ZCITY platform.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.